Bridging the gap: integrating hereditary cancer into precision oncology.
Genetic testing beyond family history reveals actionable mutations in cancer patients that directly match them to precision drugs—expanding who benefits from personalized treatment.
Germline genetic alterations in BRCA1/2, MMR genes, VHL, RET, and NF1 define actionable precision therapy targets — PARP inhibitors, immune checkpoint blockade, HIF2α inhibitors, selective RET kinase inhibitors, and RAS pathway inhibitors respectively — supporting expanded germline testing beyond traditional family history criteria. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- narrative review
- Category
- precision_oncology_genomics
- Maturity
- Exploratory
- Journal
- Eur J Hum Genet
Why it surfaced
Comprehensive precision oncology framework for hereditary cancer in Nature Publishing Group journal (EJHG). Covers multiple immediately actionable therapeutic pairs (BRCA-PARP, MMR-ICB, VHL-HIF2α) applicable across the precision oncology watchlist. Clinically actionable synthesis relevant to genomic medicine implementation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.